Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and antitumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

被引：0
|
作者：
Olszanski, A. J. [1 ]
Luke, J. J. [2 ]
LoRusso, P. M. [3 ]
Falchook, G. S. [4 ]
Bedard, P. L. [5 ]
Sanborn, R. E. [6 ]
Patel, S. P. [7 ]
Orr, D. [8 ]
Gibbs, J. P. [9 ]
Li, C. [9 ]
Huang, Y-C. [9 ]
Gregory, R. [9 ]
Perera, S. [9 ]
Xu, R. [9 ]
Joshi, A. [9 ]
Lee, M. Y. [9 ]
Raizer, J. [9 ]
Gao, X. [10 ]
机构：
[1] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA
[2] Univ Pittsburgh, Canc Immunotherapeut Ctr, Med, Pittsburgh, PA USA
[3] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[4] Sarah Cannon Res Inst SCRI HealthONE, Drug Dev Unit, Denver, CO USA
[5] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada
[6] Earle A Chiles Res Inst, Providence Canc Inst, Oncol, Portland, OR USA
[7] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[8] Mary Crowley Canc Res, Oncol, Dallas, TX USA
[9] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[10] Massachusetts Gen Hosp, Med, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029P
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [1] Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/ metastatic solid tumors: Data from phase I dose escalation
    Luke, J. J.
    Gao, X.
    Olszanski, A. J.
    Sanborn, R. E.
    Falchook, G. S.
    Patel, S.
    Bedard, P. L.
    Orr, D.
    Gibbs, J. P.
    Li, C.
    Huang, Y-C.
    Gregory, R.
    Ramesh, R.
    Xu, R.
    Wu, B.
    Ding, K.
    Raizer, J.
    Lorusso, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S678 - S679
  • [2] A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
    Falchook, Gerald Steven
    Luke, Jason J.
    Strauss, James F.
    Gao, Xin
    LoRusso, Patricia
    Voon, Pei Jye
    Li, Cong
    Shaw, Michael
    Gregory, Richard C.
    Horn, Kristin
    Gibbs, John
    Lineberry, Neil
    Stumpo, Kate
    Malek, Karim
    Olszanski, Anthony J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [4] A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors
    Goel, Sanjay
    Ulahannan, Susanna Varkey
    Olszanski, Anthony J.
    LoRusso, Patricia
    Sanborn, Rachel E.
    Sharma, Sunil
    Emens, Leisha A.
    Reilley, Matthew
    Priego, Victor
    Li, Shuli
    Wang, Bingxia
    Dong, Lixian
    Sachsenmeier, Kris
    Gibbs, John
    Gharavi, Robert
    Martinez, Alonzo
    Proscurshim, Igor
    Fram, Robert J.
    Gomez-Pinillos, Alejandro
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors
    Le Tourneau, Christophe
    Su, Wu-Chou
    Chung, Ki
    LoRusso, Patricia
    Lin, Chia-Chi
    Barlesi, Fabrice
    Shiah, Her-Shyong
    Angevin, Eric
    Spira, Alexander
    Patnaik, Amita
    Powderly, John
    Colevas, Dimitrios
    Chew, Helen
    Patel, Maulik
    Lambert, Stacie
    Li, Yan
    Da Costa, Daniel
    Blaney, Martha
    McDevitt, Michael
    Cassier, Philippe
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    Díaz-Rubio, E
    Evans, TRJ
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Bisset, D
    Regueiro, P
    Baselga, J
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 558 - 565
  • [7] A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Leong, Stephen
    Moss, Rebecca A.
    Bowles, Daniel W.
    Ware, Joseph A.
    Zhou, Jing
    Spoerke, Jill M.
    Lackner, Mark R.
    Shankar, Geetha
    Schutzman, Jennifer L.
    van der Noll, Ruud
    Voest, Emile E.
    Schellens, Jan H. M.
    ONCOLOGIST, 2017, 22 (12): : 1491 - 1499
  • [8] PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF TRANSCON TLR7/8 AGONIST ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES: INITIAL RESULTS FROM DOSE ESCALATION
    Davar, Diwakar
    Aghmesheh, Morteza
    Algazi, Alain
    Bajor, David
    Ganju, Vinod
    Laux, Douglas
    Spira, Alexander
    Ahern, Elizabeth
    Grewal, Jaspreet
    Rand, Jamie
    Sweis, Randy
    Karlsson, Jens-Jakob
    Kriegbaum, Mette
    Wu, Yang
    Tran, Tuan-Anh
    Singel, Stina
    Gabrail, Nashat
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A795 - A795
  • [9] Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study
    Traynor, A.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    VerMeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Robert, F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 110 - 110
  • [10] A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results
    Isambert, N.
    Freyer, G.
    Zanetta, S.
    Falandry, C.
    Lazard, K. Soussan
    Fumoleau, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345